Compare Repligen Corporation Common Stock (RGEN) vs Sasol Ltd. American Depositary Shares (SSL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sasol Ltd. American Depositary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Sasol Ltd. American Depositary Shares trades at $15.63 (market cap $9.94B). The key difference: Repligen Corporation Common Stock and Sasol Ltd. American Depositary Shares are close in size by market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sasol Ltd. American Depositary Shares for 2 Days on average.
| RGEN | SSL | |
|---|---|---|
Market Cap | $11.14B | $9.94B |
Volume | 1,259,263 | 1,412,509 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $15.63 |
52-Week Low | $102.87 | $5.33 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.02B | $13.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Sasol (SSL) trades at $15.58, up 1.83% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected revenue growth from $249.1B in 2025 to $272.1B in 2026. Recent developments include a sustainable aviation fuel agreement with White Desert and board changes, while the CFO's stock sales warrant monitoring.
SSL presents a compelling value opportunity with attractive valuation multiples (P/E 13.74, EV/EBITDA 5.45) and 73% analyst buy ratings. However, risks include negative cash flow trends and high RSI levels suggesting potential overbought conditions. The stock's upside depends on continued operational improvements and commodity market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sasol Ltd. American Depositary Shares
Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →
